Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec

@article{Robinson2012CanAN,
  title={Can a New Ultra-Long-Acting Insulin Analogue Improve Patient Care? Investigating the Potential Role of Insulin Degludec},
  author={Jennifer D. Robinson and Joshua J. Neumiller and R. Keith Campbell},
  journal={Drugs},
  year={2012},
  volume={72},
  pages={2319-2325}
}
The basal-bolus concept of delivering insulin to diabetic patients makes physiological sense, as it mimics normal insulin release in people without diabetes. In line with this concept, a major effort put forth by insulin manufacturers has been to develop the ideal exogenous basal insulin product. The perfect basal insulin product would be injected into subcutaneous tissue without causing irritation, release insulin continuously at a constant rate for at least 24 hours, be stable, not contribute… 
9 Citations

Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus

Trial results indicate that insulin degludec/insulin aspart may be an appropriate option for initiating insulin therapy in patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs and represents a useful advance in the treatment of type 1 or 2 diabetes.

Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus

In terms of glycaemic control, insulin degludec/insulin aspart is noninferior to insulin detemir plus insulin aspart in patients with type 1 diabetes and may also be an appropriate option for initiating insulin therapy in Patients with type 2 diabetes inadequately controlled with oral antidiabetic drugs.

Clinical utility of insulin and insulin analogs

A recent update on insulin analog structure and function is presented with an overview of the evidence on the various insulin regimens clinically used to treat diabetes and how to initiate and intensify insulin therapy.

ADHERENCIA TERAPÉUTICA Y FLEXIBILIDAD EN EL USO DE LAS INSULINAS BASALES

Although to follow a predefined plan in clinical practice is recommended, the possibility of flexibility in day to day dosage timing of this specific insulin analogue on requirement, could improve adherence in patients with a non-predictable and active social life and workday.

Ambulatory Treatment of Type 2 Diabetes in the U.S., 1997–2012

Declining sulfonylurea and glitazone use has been offset by increases in DPP-4 inhibitor use and, to a lesser degree, use of GLP-1 agonists, which has grown in complexity while older treatments continue to be replaced or supplemented by newer therapies.

Insulintherapie bei Typ 2 Diabetes mellitus (Update 2019)

The present article is a recommendation of the Austrian Diabetes Association for the practical use of insulin in type 2 diabetes, including the various insulin regimens.

Diagnostik und Therapie des Typ 1 Diabetes mellitus (Update 2019)

This guideline summarizes diagnosis of type 1 diabetes, including accompanying autoimmune disorders, insulin therapy regimens and glycemic target values.

A REVIEW ON RECENT ADVANCES IN THE TREATMENT OF DIABETES MELLITUS.

  • Medicine
  • 2022
: The previous and the newer advances performed in the management of the diabetes mellitus is reviewed shortly and the newer insulins and other hypoglycemic agents are overlooked under this review

References

SHOWING 1-10 OF 15 REFERENCES

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes

In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control.

Insulin Degludec in Type 1 Diabetes

In this clinical exploratory phase 2 trial in people with type 1 diabetes, IDeg is safe and well tolerated and provides comparable glycemic control to IGlar at similar doses, with reduced rates of hypoglycemia.

HUMAN INSULIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY: SAFETY AND HYPOGLYCÆMIC POTENCY IN HEALTHY MEN

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

Insulins can be engineered that remain soluble but become highly self-associated after injection, slowly releasing monomers; this is critically dependent on the acylation moiety.

Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes

  • [abstract no. 35-LB; online]
  • 2012